Latest Market News

Red Mountain Mining has reported encouraging exploration outcomes at its Utah Antimony Project, prompting a significant expansion of its claim holdings. The results reinforce the company's geological model and set the stage for an aggressive exploration campaign.

Bendigo and Adelaide Bank has been hit with a $50 million operational risk capital charge by APRA, while AUSTRAC launches an enforcement investigation into serious AML/CTF breaches. The bank commits to intensifying risk management efforts amid regulatory scrutiny.

Renegade Exploration has secured an option to acquire the Rooster Hill Monazite Project in Wyoming, tapping into a historically promising rare earth element resource. The move expands Renegade’s US footprint amid rising demand for critical minerals.

HealthCo Healthcare & Wellness REIT confirms full rent payment from Healthscope and has conditional agreements with alternative tenants for its hospital portfolio, while suspending its December quarter distribution to preserve liquidity.

American Uranium Limited has successfully expanded uranium mineralisation trends by 3,000 metres at its Lo Herma ISR Project in Wyoming, delivering its strongest drill intercept to date and setting the stage for a 2026 resource update and scoping study.

International Graphite Limited has secured development approval for its Collie graphite processing facility, marking a significant step toward integrated graphite production in Western Australia.

GemLife has secured a $21 million greenfield site in Townsville, Queensland, aiming to develop over 500 new homes and boost its Land Lease Community portfolio.

Perpetual Limited has extended its exclusivity agreement with Bain Capital into early 2026 as discussions continue over the potential sale of its Wealth Management business. While progress is steady, no binding deal is yet assured.

PhosCo has completed a key drilling program at its Gasaat Phosphate Project in Tunisia, with promising phosphate intersections at the SAB prospect and imminent assay results from KM, setting the stage for updated resource estimates and an enhanced project outlook.

Actinogen Medical has finalized enrollment and begun treatment of all 246 participants in its XanaMIA Phase 2b/3 Alzheimer’s trial, with topline results expected in November 2026. The oral drug Xanamem targets brain cortisol to potentially slow disease progression.

The Calmer Co. International Limited has completed a $1.4 million convertible note raise, positioning itself to accelerate wholesale growth and inventory build ahead of 2026.

RAS Technology Holdings will not renew its Complete Racing Solution contract with Stake in 2026, shifting focus to expanding in regulated markets and Asia’s burgeoning racing sector.